Akari Therapeutics raises CEO Abizer Gaslightwala base salary to $625,000

• Akari Therapeutics amended CEO Abizer Gaslightwala’s employment agreement on Sept. 29, 2026.
• Annual base salary raised to $625,000 effective Aug. 18, 2026; $62,500 to be paid in RSUs over 12 months.
• Target annual bonus opportunity increased to 55% of base salary; target salary and bonus totals about $970,000.
• Equity package includes options for 174,000 ADSs dated Aug. 18, 2026; monthly vesting over four years from March 18, 2026.
• RSUs and options hinge on shareholder approval to expand ADSs available under the 2023 Equity Incentive Plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-045364), on October 01, 2026, and is solely responsible for the information contained therein.